BiotechTube

CB-03-10

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Refractory Solid Tumors

Conditions

Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10

Trial Timeline

Jun 14, 2022 → Jun 1, 2026

NCT ID
NCT03863145

About CB-03-10

CB-03-10 is a phase 1 stage product being developed by Cosmo Pharmaceuticals for Advanced Refractory Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03863145. Target conditions include Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03863145Phase 1Recruiting

Competing Products

20 competing products in Advanced Refractory Solid Tumors

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Cosmo Pharmaceuticals

Methylene Blue MMX 25 mg modified release tabletsPhase 2
47
Rifamycin SV 600mg t.i.d. + Rifamycin SV b.i.d. + Placebo + Placebo t.i.d.Phase 2
47
400 mg Rifamycin SV dosage + 800 mg Rifamycin SV dosage + 1200 mg Rifamycin SV dosagePhase 2
47